| CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ... Nature communications 8 (1), 15916, 2017 | 278 | 2017 |
| Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer JPW Carey, C Karakas, T Bui, X Chen, S Vijayaraghavan, Y Zhao, J Wang, ... Cancer research 78 (3), 742-757, 2018 | 125 | 2018 |
| Paget's disease of the breast C Karakas Journal of carcinogenesis 10, 2011 | 121 | 2011 |
| Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition X Chen, KH Low, A Alexander, Y Jiang, C Karakas, KR Hess, JPW Carey, ... Clinical Cancer Research 24 (24), 6594-6610, 2018 | 104 | 2018 |
| Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells KS Lucenay, I Doostan, C Karakas, T Bui, Z Ding, GB Mills, KK Hunt, ... Cancer research 76 (8), 2406-2418, 2016 | 76 | 2016 |
| A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer Z Mitri, C Karakas, C Wei, B Briones, H Simmons, N Ibrahim, R Alvarez, ... Investigational new drugs 33, 890-894, 2015 | 75 | 2015 |
| Cytoplasmic cyclin E predicts recurrence in patients with breast cancer KK Hunt, C Karakas, MJ Ha, A Biernacka, M Yi, AA Sahin, O Adjapong, ... Clinical Cancer Research 23 (12), 2991-3002, 2017 | 57 | 2017 |
| Cytoplasmic cyclin E and phospho–cyclin-dependent kinase 2 are biomarkers of aggressive breast cancer C Karakas, A Biernacka, T Bui, AA Sahin, M Yi, S Akli, J Schafer, ... The American Journal of Pathology 186 (7), 1900-1912, 2016 | 55 | 2016 |
| Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer A Alexander, C Karakas, X Chen, JPW Carey, M Yi, M Bondy, ... Oncotarget 8 (9), 14897, 2017 | 46 | 2017 |
| Molecular mechanisms involving prostate cancer racial disparity C Karakas, C Wang, F Deng, H Huang, D Wang, P Lee American journal of clinical and experimental urology 5 (3), 34, 2017 | 45 | 2017 |
| Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay V Müller, C Thomssen, C Karakas, I Eustermann, JR Porras, C Coith, ... The International journal of biological markers 18 (1), 13-20, 2003 | 40 | 2003 |
| Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer I Doostan, C Karakas, M Kohansal, KH Low, MJ Ellis, JA Olson Jr, ... Clinical Cancer Research 23 (23), 7288-7300, 2017 | 36 | 2017 |
| HER2-low breast cancers: Current insights and future directions H Zhang, C Karakas, H Tyburski, BM Turner, Y Peng, X Wang, H Katerji, ... Seminars in Diagnostic Pathology 39 (5), 305-312, 2022 | 32 | 2022 |
| Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence JA Caruso, C Karakas, J Zhang, M Yi, C Albarracin, A Sahin, M Bondy, ... Breast Cancer Research 16, 1-14, 2014 | 31 | 2014 |
| Targeting replicative stress and DNA repair by combining PARP and Wee1 kinase inhibitors is synergistic in triple negative breast cancers with cyclin E or BRCA1 alteration X Chen, D Yang, JPW Carey, C Karakas, C Albarracin, AA Sahin, BK Arun, ... Cancers 13 (7), 1656, 2021 | 24 | 2021 |
| Dedifferentiated gastrointestinal stromal tumor: recent advances C Karakas, P Christensen, D Baek, M Jung, JY Ro Annals of Diagnostic Pathology 39, 118-124, 2019 | 24 | 2019 |
| Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-Low–Expressing breast cancer cohort C Karakas, H Tyburski, BM Turner, X Wang, LM Schiffhauer, H Katerji, ... American Journal of Clinical Pathology 159 (5), 484-491, 2023 | 23 | 2023 |
| Determination of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2, Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma, and … P Temiz, G Akkaş, N Neşe, FU Duman, C Karakaş, Y Erhan Turkish Journal of Medical Sciences 45 (4), 865-871, 2015 | 22 | 2015 |
| PKCiota promotes ovarian tumor progression through deregulation of cyclin E A Nanos-Webb, T Bui, C Karakas, D Zhang, JPW Carey, GB Mills, ... Oncogene 35 (19), 2428-2440, 2016 | 21 | 2016 |
| Cytoplasmic cyclin E expression predicts for response to neoadjuvant chemotherapy in breast cancer C Karakas, AM Francis, MJ Ha, HF Wingate, RA Meena, M Yi, ... Annals of surgery 274 (2), e150-e159, 2021 | 7 | 2021 |
